Cipla Ltd

Cipla Employee Stock Options

Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.

Cipla Management Change

Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.

Cipla Other Announcement

Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.

Cipla Acquisition

Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.

Cipla Earnings Call Transcript: Key Takeaways

Cipla delivered record Q1 FY27 revenue of INR 7,119 Cr with 2% reported growth (4% adjusted). Strategy focuses on U.S. respiratory launches and 'One India' chronic therapies.

Cipla Investor Presentation: Key Takeaways

Cipla delivered record Q1 revenue of INR 7,119 Cr, driven by strong growth in India and the US. EBITDA margins stood at 16.7% with PAT at INR 789 Cr.

Cipla Q1 FY27 Results: Net Profit ₹785.5 Cr, Down 39.2% YoY

Cipla Ltd reported revenue from operations of ₹7,119 Cr (+2.3% YoY) and net profit of ₹785.5 Cr (-39.2% YoY) for Q1 FY27.

Key figure

Net profit ₹785.5 Cr · -39.2% YoY

Cipla Earnings Call: Key Takeaways

Cipla delivered highest-ever yearly revenue of ₹28,163 Cr in FY26, despite multiple headwinds. Strategy focuses on India growth, US pipeline expansion, and ESG goals.

Cipla Q4 FY26 Results: Net Profit ₹542.5 Cr, Down 55.3% YoY

Cipla Ltd reported revenue from operations of ₹6,541 Cr (-2.8% YoY) and net profit of ₹542.5 Cr (-55.3% YoY) for Q4 FY26.

Key figure

Net profit ₹542.5 Cr · -55.3% YoY